Investors Face Losses After GeneDx Acquisition Fallout

The lawsuit, filed in the United States District Court for the District of Connecticut under the caption Taher Basma v. GeneDx Holdings Corp., covers investors who purchased WGS common stock between April 16, 2025, and May 4, 2026. Plaintiffs allege that GeneDx executives provided false or misleading statements concerning the integration and operational health of Fabric Genomics, an AI-driven genomic interpretation firm purchased in 2025.

Market confidence evaporated on May 4, 2026, when GeneDx reported its first-quarter results. The disclosure revealed significant issues, including lower-than-expected reimbursement rates and shrinking adjusted gross margins. Most notably, the company reported a $31.3 million write-off tied to the Fabric acquisition—an amount nearly equal to the initial cash outlay. Kessler Topaz Meltzer & Check, LLP is currently advising affected shareholders on their legal options. Investors seeking to serve as lead plaintiff in the class action must file their applications by August 3, 2026.